Trial · NCT07419373
ARN-75039 Lassa Fever Treatment in West Africa
NCT07419373, Phase 2, Suspended, Arisan Therapeutics, Inc.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. ARN-75039 Lassa Fever Treatment in West Africa. Trials, record NCT07419373. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07419373
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- ARN-75039 Lassa Fever Treatment in West Africa
- NCT number
- NCT07419373
- Status
- Suspended
- Phases
- Phase 2
- Enrollment
- 135 participants, estimated
- Lead sponsor
- Arisan Therapeutics, Inc.
- Conditions
- Lassa Fever
- Interventions
- ARN-75039 high, Intravenous ribavirin, ARN-75039 low
- First posted
- 2026-02-19
- Last updated
- 2026-07-06
Source ClinicalTrials.gov
Registered outcomes36
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of Treatment-Emergent Adverse Events (TEAEs) Grade ≥3 | Day 1 through Day 28 | Type and frequency of treatment-emergent adverse events of Grade 3 or higher |
| Primary | Change in Viral Load Slope (RT-PCR Ct Values) | Day 1 to Day 10 | Change in slope of Lassa virus RT-PCR cycle threshold (Ct) values between Day 1 and Day 10 in participants with low baseline Ct values. |
| Secondary | Change in Viral Load Slope in Participants with Other Baseline Ct Values | Day 1 to Day 10 | Change in slope for LASV RT-PCR Ct values between Day 1 and Day 10, for subjects with other baseline Ct values (to be determined \[TBD\], subsequent to RT-PCR methods validation). |
| Secondary | Change in RT-PCR Ct Values at Prespecified Timepoints (Change in Ct values. between Day 1 and Days 2, 3, 4, 6, 8, and 10). | Day 1 to Day 10 | Change in Ct values between Day 1 and each of Days 2, 3, 4, 6, 8, and 10 for the ARN-75039 arms vs SOC for those with baseline Ct \<30 (or other Ct values TBD). |
| Secondary | Time to First RT-PCR Result Below Lower Limit of Quantification (LLOQ) | Day 1 to Day 28 | Time to reach lower limit of quantification \[LLOQ\] and undetectable Ct values. |
| Secondary | Time to First Undetectable Lassa Virus RT-PCR Result | Day 1 to Day 28 | Time to reach undetectable Ct values. |
| Secondary | Proportion of Participants With RT-PCR <LLOQ | Day 1 to Day 28 | LASV RT-PCR \<LLOQ (% of participants) for specified baseline Ct values (TBD). |
| Secondary | Proportion of Participants With Undetectable RT-PCR | Day 1 to Day 28 | LASV RT-PCR undetectable (% of participants) for specified baseline Ct values TBD. |
| Secondary | Estimated Baseline Lassa Virus RT-PCR Cycle Threshold (Ct) Value (Intercept) from Linear Mixed-Effects Model | Day 1 | Estimated baseline Lassa virus RT-PCR cycle threshold (Ct) value derived from a linear mixed-effects model of longitudinal Ct measurements collected between Day 1 and Day 10. Results will be reported as model-estimated mean Ct value (Ct units). |
| Secondary | Estimated Rate of Change in Lassa Virus RT-PCR Ct Value (Ct Units per Day) from Linear Mixed-Effects Model. | Day 1 to Day 10 | Estimated rate of change (slope) in Lassa virus RT-PCR cycle threshold (Ct) values over time, calculated using a linear mixed-effects model of longitudinal Ct measurements from Day 1 through Day 10. Results will be reported as mean change in Ct units per day (Ct/day). |
1 to 10 of 36Source ClinicalTrials.gov
See all 36 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07419373
GET https://conductscience.org/api/trials/v1/NCT07419373/registered?page=2